Follicular Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT02417285: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Checkmark For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Checkmark In R/R DLBCL or iNHL at ASH 2016
Dec 2016 - Dec 2016: In R/R DLBCL or iNHL at ASH 2016
Completed
1b
75
Europe
Obinutuzumab, GA-101, CC-122
Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
05/19
09/23
NCT01680991: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Completed
1
48
RoW
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
12/14
12/14
GAUDI, NCT00825149: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark relapsed/refractory follicular lymphoma
Jul 2013 - Jul 2013: relapsed/refractory follicular lymphoma
Checkmark P1 data in FL
More
Completed
1
137
Europe, RoW
Bendamustine, Cyclophosphamide, Doxorubicin, Fludarabine, Obinutuzumab, RO5072759, Prednisone, Vincristine
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
11/15
11/15
NCT03369964: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn
1
0
US
Atezolizumab, Emactuzumab, Obinutuzumab
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
12/18
08/19
NCT02220842: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Checkmark Data from trial in combination with Tecentriq in r/r DLBCL at ICML 2019
Jun 2019 - Jun 2019: Data from trial in combination with Tecentriq in r/r DLBCL at ICML 2019
Checkmark Tazemetostat and Tecentriq in combination for r/r DLBCL
Jul 2016 - Dec 2016: Tazemetostat and Tecentriq in combination for r/r DLBCL
Checkmark EHA 2016
More
Completed
1
96
Europe, US
Atezolizumab, Tecentriq, Obinutuzumab, Tazemetostat, EPZ6438
Hoffmann-La Roche
Lymphoma
01/20
01/20
SAKK 35/15, NCT02877550: Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Completed
1
25
Europe
Obinutuzumab, GA101, Gazyvaro, Gazyva, Venetoclax, ABT-199, GDC-0199, Venclexta
Swiss Group for Clinical Cancer Research
Follicular Lymphoma
04/20
05/22
CITADEL-102, NCT03039114: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Completed
1
26
Europe, US, RoW
Parsaclisib, INCB050465, Hexal, Bendamustine, Gazyvaro, Gazyva®, Obinutuzumab
Incyte Corporation
Lymphoma
03/21
03/21
NCT02992522: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
22
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Beth Christian, Celgene, Genentech, Inc.
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
12/24
12/24
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
4
US
Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
04/24
12/24
LOTIS 7, NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Recruiting
1
200
Europe, US, RoW
Loncastuximab Tesirine, ZYNLONTA, ADCT-402, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
ADC Therapeutics S.A.
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
02/25
02/26
NCT05653271: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Recruiting
1
42
US, RoW
Cyclophosphamide, Fludarabine, ACE1831, Obinutuzumab
Acepodia Biotech, Inc.
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma
09/25
09/27
NCT04599634: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Active, not recruiting
1
1
US
Obinutuzumab, Venetoclax, Magrolimab
National Cancer Institute (NCI)
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
03/24
02/27

Download Options